Immunology beats cancer: a blueprint for successful translation

Nat Immunol. 2012 Dec;13(12):1129-32. doi: 10.1038/ni.2392.

Abstract

Immunology offers an unprecedented opportunity for the science-driven development of therapeutics. The successes of antibodies to the immunomodulatory receptor CTLA-4 and blockade of the immunoinhibitory receptor PD-1 in cancer immunotherapy, from gene discovery to patient benefit, have created a paradigm for driving such endeavors.

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • CTLA-4 Antigen / immunology*
  • Humans
  • Immunotherapy
  • Ipilimumab
  • Melanoma / immunology
  • Melanoma / therapy
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • Programmed Cell Death 1 Receptor / immunology*
  • T-Lymphocytes / immunology
  • Translational Medical Research

Substances

  • Antibodies, Monoclonal
  • CTLA-4 Antigen
  • Ipilimumab
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor